Compare Sana Biotechnology Inc (SANA) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Workiva Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Workiva Inc trades at $55.02 (market cap $3.21B). The key difference: Workiva Inc is far larger — about 3.7× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SANA | WK | |
|---|---|---|
Market Cap | $873.84M | $3.21B |
Sector | Health | Technology |
52-Week High | $5.92 | $93.31 |
52-Week Low | $2.68 | $44.31 |
Enterprise Value | $848.03M | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Workiva (WK) trades at $57.19, showing minimal daily movement with a 0.02% gain. The stock maintains a bullish technical outlook with strong analyst support (88.9% buy ratings) and a $71 consensus price target. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.77 surpassing the $0.66 estimate. Revenue growth continues with 2026 projections showing $926 million and a return to profitability at 1.53% net margin.
The outlook remains positive given Workiva's dominant market position in compliance software and AI-powered platform growth. Key risks include high valuation multiples (P/E 238.25) and competitive pressures in the enterprise software space. The stock offers 24% upside to consensus targets but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
